Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Top Cited Papers
Open Access
- 1 April 2008
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 10 (2) , 162-170
- https://doi.org/10.1215/15228517-2007-062
Abstract
The North American Brain Tumor Consortium (NABTC) uses 6-month progression-free survival (6moPFS) as the efficacy end point of therapy trials for aduKeywords
This publication has 5 references indexed in Scilit:
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- A design of phase II cancer trials using total and complete response endpointsStatistics in Medicine, 2005
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990